Disrupting Disease at the Cellular Source
Traditional brain cancer therapies often fail because they target the rapidly dividing cells of the tumor mass but leave behind a highly resilient subpopulation of cells known as Cancer Stem Cells (CSCs). These cells act as the fundamental source of the tumor, driving inevitable disease recurrence.
Image credit: Terrence Johns, PhD
GBM cancer cells with OLIG2 (green) in the nucleus of the cells.
Image credit: Human Protein Atlas, www.proteinatlas.org. Image available from v25.proteinatlas.org/ENSG00000205927-OLIG2/subcellular
The Role of OLIG2
In many aggressive CNS malignancies, the survival of CSCs is driven by a master control switch: the OLIG2 transcription factor. OLIG2 not only fuels the unchecked growth of these CSCs but also manipulates the tumor micro-environment, actively suppressing the body's natural immune response and hiding the tumor from attack.
CT-179: A Dual-Action Breakthrough
Curtana’s lead asset, CT-179, is an orally administered, highly CNS-penetrant small molecule specifically designed to target OLIG2. By neutralizing this critical pathway, CT-179 delivers a dual-action strike:
Action 1
Eradicating Cancer Stem Cells
It directly kills the OLIG2-expressing CSCs, destroying the primary source responsible for tumor recurrence.
Action 2
Reversing Immune Suppression
By silencing OLIG2's influence on the microenvironment, CT-179 reverses tumor-driven immune suppression, turning a "cold" tumor environment "hot" and equipping the body’s innate immune system to fight back.